Pembrolizumab I. V

The STATE COMPANY FOR MARKETING DRUGS MEDICAL APPLIANCES in Iraq from Middle East region had released this tender for Tenders are invited for Pembrolizumab 100 Mg Vial I. V. 1 15-B00-104 Pembrolizumab 100 mg vial I.V The company supplying any of the aforementioned treatments is committed to providing the following for free 1- Free PDL1 examination inside Iraq, at the rate of 1000 examinations with each contract 2- Free EGFR examination inside Iraq, at the rate of 1000 examinations with each contract 3- Free ALK examination inside Iraq, at the rate of 1000 examinations with each contract 4- Two laboratory testing devices, for one time only, with training for technical and health personnel, with warranty and maintenance throughout the contract period. Subsequent to session 1133, Paragraph (2) First / 4 that the specifications of the laboratory equipment required in the above paragraph are as attached to session 1161, and their use is limited to treating cases of metastatic melanoma Metastatic triple negative breast cancer Metastatic head and nrc cancer Metastatic non-small lung cancer As a monotherapy first line (PD-L1≥50) according to a treatment protocol prepared for this purpose by the Advisory Committee for Therapeutic Radiology 40000 1 vial 2300 1610 1035 575 Payment of a nonrefundable fee with lump sum as follows: a- (1.000.000)one million Iraqi Dinar of the tender that less than (1.000.000) Dollars b- (2.000.000)two million Iraqi Dinar for the tender that more than (1.000.000) Dinar A Bid Security at ratio 1% Closing Date: 18/5/2023 with tender notice no. Med9/2023/A published on 11 May 2023. The tender expired on 18 May 2023. This tender is sourced from Official Website and is eligible for suppliers interested in Pharmaceutical products. Interested bidders can obtain further information including complete bid documents or ways to participate by registering on Tender Impulse and referencing via Tender Impulse ID 3111639.